SIGA Technologies CSO to Speak at The 13th CBRNe Protection Symposium on September 25, 2019
Dr. Hruby will deliver a presentation titled TPOXX for the Treatment of Smallpox at 4:20 P.M. Central European Summer Time on Wednesday, September 25, 2019.
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis E. Hruby, the Company’s Chief Scientific Officer, will be a speaker at the 13th Chemical, Biological, Radiological, Nuclear, and Explosive materials (CBRNe) Protection Symposium in Malmö, Sweden.
Dr. Hruby will deliver a presentation titled “TPOXX® for the Treatment of Smallpox” at 4:20 P.M. Central European Summer Time on Wednesday, September 25, 2019. “I am pleased to have the opportunity to share information about the potential role that TPOXX could play in addressing a smallpox outbreak with global colleagues in the field of bio-preparedness,” said Dr. Hruby. “We believe that ongoing interactions and information sharing with companies and government agencies focused on developing effective responses to potential bioterror threats will support SIGA’s efforts to increase interest in and demand for TPOXX among potential international customers.”
ABOUT SIGA TECHNOLOGIES, INC. and TPOXX®
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug of which more than 2 million oral courses have been delivered to the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox on July 13, 2018. The full label is here:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf.
In September 2018, SIGA signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for procurement of oral and intravenous formulations of TPOXX, and development activities. For more information about SIGA, please visit www.siga.com.
About Smallpox1
Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally-occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine's side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.
FORWARD-LOOKING STATEMENTS
This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.
Contacts:
Investors
David Carey
212-867-1768
[email protected]
Media
Stephanie Seiler
206-713-0124
[email protected]
1http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769
